34 results about "Antituberculous drug" patented technology

The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.

The invention discloses a substituted N-((1', 3'-azole-4'-yl)-methyl)-4-benzoyl-hexahydropyridine compound represented by formula I, a preparation method thereof, and applications of the substituted N-((1', 3'-oxazole-4'-yl)-methyl)-4-benzoyl-hexahydropyridine compound in preparation of antituberculous drugs. The substituted N-((1', 3'-azole-4'-yl)-methyl)-4-benzoyl-hexahydropyridine compound possesses activity on mycobacterium tuberculosis-susceptible strains, and also possesses activity on strains with tolerance on traditional first-line antituberculous drugs such as isoniazide and rifampicin, and is a novel mycobacterium tuberculosis resistant compound with a promising application prospect.

The invention relates to mycobacterium tuberculosis antigen protein Rv1798 and application of a T cell epitope peptide of the mycobacterium tuberculosis antigen protein Rv1798 in preparation of tuberculosis detection reagents, vaccines and drugs. An amino acid sequence of the mycobacterium tuberculosis protein antigen Rv1798 and an amino acid sequence of the T cell epitope peptide of the protein antigen Rv1798 are shown in SEQ ID NO:1-3 respectively. The mycobacterium tuberculosis protein antigen Rv1798 and the T cell epitope peptide thereof are applied to a specific T cell and B cell immune response caused by mycobacterium tuberculosis by serving as irritants; and when the mycobacterium tuberculosis protein antigen Rv1798 and the T cell epitope peptide thereof are applied to the specific T cell and B cell immune response caused by the mycobacterium tuberculosis by serving as the irritants, the condition that a false positive result is caused due the fact that an antigen is not pure can be reduced compared with an original method that a complete antigen is adopted. The detection reagents prepared from the protein antigen Rv1798 and the epitope peptide thereof can be widely applied to the related fields of assistant diagnosis of tuberculosis, epidemiological monitoring and the like. The tuberculosis vaccines and the antituberculous drugs which are prepared from the protein antigen Rv1798 can be used for preventing and treating the tuberculosis.